Form 4: Karyopharm Therapeutics SVP Michael Mano Reports Sale of Shares to Cover Tax Obligations

Michael Mano, SVP, General Counsel & Secretary of Karyopharm Therapeutics, reported selling 2,793 shares of common stock on March 4, 2025, to cover withholding tax liabilities.

Summary

• On March 4, 2025, Michael Mano, SVP, General Counsel & Secretary of Karyopharm Therapeutics Inc. (KPTI), sold 2,793 shares of common stock.
• The sale was executed at a weighted average price of $6.29 per share, with individual transactions ranging from $6.11 to $6.31.
• The transaction was conducted under a pre-arranged automatic sale plan adopted on May 16, 2022, to cover withholding tax obligations arising from the vesting of restricted stock units.
• Following the reported transaction, Mano directly owns 21,047 shares of Karyopharm Therapeutics Inc.

Sentiment

Score: 6

Explanation: Neutral sentiment as the filing reflects a routine transaction for tax purposes and doesn't indicate any strategic shift or concern.

Industry Context

Form 4 filings are standard practice and provide transparency into the transactions of company insiders. This sale appears to be routine, related to tax obligations.

Stakeholder Impact

• The sale of shares by an insider could have a minor impact on shareholder sentiment, but given the context (tax obligations, pre-arranged plan), the impact is likely to be minimal.

Key Dates